Halozyme Therapeutics Stock Alpha and Beta Analysis
| HALO Stock | USD 49.00 3.30 7.22% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Halozyme Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Halozyme Therapeutics over a specified time horizon. Remember, high Halozyme Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Halozyme Therapeutics' market risk premium analysis include:
Beta 1.62 | Alpha (0.48) | Risk 3.8 | Sharpe Ratio (0.09) | Expected Return (0.32) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Halozyme |
Halozyme Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Halozyme Therapeutics market risk premium is the additional return an investor will receive from holding Halozyme Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Halozyme Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Halozyme Therapeutics' performance over market.| α | -0.48 | β | 1.62 |
Halozyme Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Halozyme Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Halozyme Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Halozyme Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how Halozyme Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Halozyme Therapeutics shares will generate the highest return on investment. By understating and applying Halozyme Therapeutics stock market price indicators, traders can identify Halozyme Therapeutics position entry and exit signals to maximize returns.
Halozyme Therapeutics Return and Market Media
The median price of Halozyme Therapeutics for the period between Tue, Aug 27, 2024 and Mon, Nov 25, 2024 is 58.16 with a coefficient of variation of 9.63. The daily time series for the period is distributed with a sample standard deviation of 5.42, arithmetic mean of 56.29, and mean deviation of 4.6. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Disposition of 7471 shares by Michael LaBarre of Halozyme Therapeutics at .542 subject to Rule 16b-3 | 08/30/2024 |
2 | Acquisition by Duncan Barbara Gayle of 6501 shares of Halozyme Therapeutics subject to Rule 16b-3 | 09/06/2024 |
3 | Disposition of 10000 shares by Torley Helen of Halozyme Therapeutics at 13.87 subject to Rule 16b-3 | 09/10/2024 |
4 | Disposition of 10000 shares by Michael LaBarre of Halozyme Therapeutics at 16.65 subject to Rule 16b-3 | 09/18/2024 |
5 | Disposition of 10000 shares by Posard Matthew L. of Halozyme Therapeutics at 50.011 subject to Rule 16b-3 | 09/27/2024 |
6 | HALO COLLAR ANNOUNCES HALO COLLAR 4 | 09/30/2024 |
7 | Disposition of 5509 shares by Michael LaBarre of Halozyme Therapeutics at 16.65 subject to Rule 16b-3 | 10/15/2024 |
8 | Halozyme Therapeutics CTO sells shares worth over 1 million | 10/16/2024 |
9 | Heres How Much a 1000 Investment in Halozyme Therapeutics Made 10 Years Ago Would Be Worth Today | 11/08/2024 |
10 | HALO Stock Dips 5.77 percent Amid Biotech Sector Changes | 11/14/2024 |
11 | Why Is Evotec Facing a Takeover Amid Financial Challenges | 11/15/2024 |
12 | Halozyme Provides Update on Non-Binding Proposal to Combine with Evotec | 11/18/2024 |
13 | Evotec stock plunges amid report its against Halozyme Therapeutics takeover | 11/19/2024 |
14 | Heres Why Halozyme Therapeutics is a Strong Value Stock | 11/21/2024 |
About Halozyme Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Halozyme or other stocks. Alpha measures the amount that position in Halozyme Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2021 | 2022 | 2023 | 2024 (projected) | Payables Turnover | 52.83 | 7.87 | 16.28 | 17.09 | Days Of Inventory On Hand | 241.69 | 262.34 | 242.12 | 230.01 |
Halozyme Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Halozyme Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Halozyme Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Halozyme Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Halozyme Therapeutics. Please utilize our Beneish M Score to check the likelihood of Halozyme Therapeutics' management manipulating its earnings.
| 20th of February 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 20th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Halozyme Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Halozyme Therapeutics Backtesting, Halozyme Therapeutics Valuation, Halozyme Therapeutics Correlation, Halozyme Therapeutics Hype Analysis, Halozyme Therapeutics Volatility, Halozyme Therapeutics History and analyze Halozyme Therapeutics Performance. To learn how to invest in Halozyme Stock, please use our How to Invest in Halozyme Therapeutics guide.You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Halozyme Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.